Compare Organon & Co. Common Stock (OGN) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs AT&T Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while AT&T Inc. trades at $23.09 (market cap $156.58B). The key difference: AT&T Inc. is far larger — about 43.3× Organon & Co. Common Stock's market cap, and AT&T Inc. pays the higher dividend (4.86%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| OGN | T | |
|---|---|---|
Market Cap | $3.62B | $156.58B |
Volume | 2,892,999 | 46,597,672 |
Sector | Health | Media |
52-Week High | $13.81 | $29.10 |
52-Week Low | $5.70 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $11.04B | $301.90B |
Dividend Yield | 0.58% | 4.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
AT&T (T) trades at $23.08, up 2.62% today, with strong fundamentals including a P/E of 7.54 and net income margin of 16.94%. Recent earnings beat expectations, with Q2 2026 EPS of $0.65 versus $0.59 expected. Technical indicators show a bearish overall signal despite bullish oscillators. The company maintains robust cash flow with $15.12B net cash flow in 2025 and recently announced a $3B fiber deal with Corning to support AI infrastructure growth.
Outlook remains mixed with analyst consensus price target of $27.39 offering 19% upside potential, though technical weakness and competitive pressures pose risks. The stock's 4% dividend yield provides income support, but debt levels and legacy revenue declines require monitoring. Fiber expansion and wireless growth present opportunities amid challenging market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
